Xspray Pharma Q2 2024: Another CRL but long term assymetric risk/reward remains - Redeye

Redeye updates its view on Xspray following the Dasynoc CRL and the Q2 report. Adjustments to our valuation model, including a postponed launch and additional equity funding to maintain the development pace in the pipeline, have resulted in a lower fair value range. However, the upside remains significant if things unfold somewhat according to our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1027685/xspray-pharma-q2-2024-another-setback-but-the-long-term-risk-reward-remains-assymetric?utm_source=finwire&utm_medium=RSS